Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study.
hypoglycemia
if-diabete
metabolic control
telemedicine
type 1 diabetes
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
12 Jan 2021
12 Jan 2021
Historique:
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
epublish
Résumé
Background The IF-DIABETE system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-DIABETE system in improving clinical and metabolic outcomes in individuals with type 1 diabetes. Methods This is a prospective nonrandomized single-arm pilot study. Our patients used the IF-DIABETE smartphone application as a novel bolus calculator. Over six months period of the study, the primary outcome considered was hemoglobin glycated (HbA1c), and we identified hypoglycemic events, body mass index (BMI), and the frequency of blood glucose measurements as secondary outcomes. Results Twenty-one patients with type 1 diabetes were enrolled. The average age was 21 ± 3 years. Over a six months' period of the study, the mean HbA1c level decreased from 8.3 ± 0.8% to 7.0 ± 0.5 % with a reduction in mild hypoglycemic events' frequency from 5 ± 3 to 1 ± 0.7 episodes/3 months. We did not observe any change in BMI and the frequency of the blood glucose testing improved from 2 ± 0.5 to 5 ± 1 tests per day. Conclusion The IF-DIABETE system was safe and effective to support individuals who have type 1 diabetes to improve their metabolic control. At six months, patients were able to improve their glycemic control without increasing the risk of hypoglycemic events.
Identifiants
pubmed: 33585132
doi: 10.7759/cureus.12646
pmc: PMC7872867
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12646Informations de copyright
Copyright © 2021, Rouf et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Diabetes Care. 2003 Apr;26(4):1176-80
pubmed: 12663593
J Eval Clin Pract. 2008 Jun;14(3):465-9
pubmed: 18373577
Diabetes. 1996 Oct;45(10):1289-98
pubmed: 8826962
Diabetes Technol Ther. 2009 Feb;11(2):99-106
pubmed: 19848576
Diabetes Care. 2005 Nov;28(11):2697-702
pubmed: 16249542
Diabetes Care. 2018 Jan;41(Suppl 1):S55-S64
pubmed: 29222377
Diabetes Care. 2010 Jan;33(1):109-15
pubmed: 19808926
J Am Board Fam Med. 2007 Jul-Aug;20(4):375-84
pubmed: 17615418
Diabetes Care. 1995 May;18(5):625-30
pubmed: 8585999
Diabetes Care. 1995 Nov;18(11):1415-27
pubmed: 8722064
Int J Clin Pract. 2010 Jul;64(8):1121-9
pubmed: 20236369
Diabetes Technol Ther. 2012 Jun;14 Suppl 1:S51-8
pubmed: 22650225
Diabet Med. 2015 Dec;32(12):1658-61
pubmed: 26103794
Diabetes Care. 2004 May;27(5):1088-94
pubmed: 15111526
Am J Med. 1991 Apr;90(4):450-9
pubmed: 2012085
Comput Methods Programs Biomed. 2001 Mar;64(3):175-87
pubmed: 11226615
Telemed J E Health. 2008 Apr;14(3):273-9
pubmed: 18570552
Diabetologia. 1997 Aug;40(8):926-32
pubmed: 9267987
Diabetologia. 1983 Dec;25(6):470-6
pubmed: 6363175
Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S358-72
pubmed: 11460584
Diabetes Care. 2011 Mar;34(3):533-9
pubmed: 21266648
BMC Health Serv Res. 2016 Sep 29;16(1):524
pubmed: 27683021
Int J Artif Organs. 2006 Nov;29(11):1074-81
pubmed: 17160965
Diabetes Technol Ther. 2009 Apr;11(4):211-7
pubmed: 19344195
BMJ. 2002 Oct 5;325(7367):746
pubmed: 12364302
Comput Methods Programs Biomed. 2002 Aug;69(2):137-46
pubmed: 12100793